We bring the fight to bacteria
The WHO has declared that AMR is one of the top 10 global public health threats facing humanity and our unified economic structures. Felix recognizes that now is the moment to tackle this crucial problem.
The WHO has declared that AMR is one of the top 10 global public health threats facing humanity and our unified economic structures. Felix recognizes that now is the moment to tackle this crucial problem.
Design and deploy phages to kill life threatening bacterial infections.
Protect the world against the coming threat of antimicrobial resistance.
Produce programmable therapies that harness the power of evolution to kill resistant bacteria.
Our version 1.0 asset treating Pseudomonas aeruginosa infections in cystic fibrosis patients has been used in patients (like Paige) and is currently being tested in a controlled, blinded clinical trial.
Our treatment has shown the potential to improve lung function, decrease lung microbial load and, in many cases, decrease bacterial virulence.
Paige Rogers – survived an antimicrobial resistant lung infection with the help of our Phage 1.0 treatment
Antimicrobial resistance is a growing global threat endangering healthcare systems and economic prosperity if unchecked. The majority of phage therapies under development are personalized, expensive, and difficult to scale. From day one, our approach has been to create generalized, broadly applicable phage therapies - treatments that could be shipped around the world and administered as easily as a pill.
Our team is inspired to solve the challenge of life-threatening resistant infections using our unique combination of passion and knowledge about phage, phage-antibiotic combinations and our advanced platform supporting analysis of genotypes and phenotypes at scale.
We’re building a technical team of scientists and engineers who are passionate about working on world-saving problems.
Careers